News Release

BAXTER RECEIVES EUROPEAN LICENSURE FOR CEPROTIN,
A TREATMENT FOR PROTEIN C DEFICIENCY

Brussels, Belgium, July 18, 2001 - Baxter International Inc. announced today that the European Medicines Evaluation Agency (EMEA) has granted licensure for Ceprotin, protein C concentrate, for use as a replacement therapy for people suffering from life-threatening blood clotting complications related to severe congenital protein C deficiency. Baxter is the first company to receive a license using the European centralized procedure, a process by which the European Commission grants authorization which is valid in all member states of the European Union.

"Continuing our legacy of 'firsts,' we are proud to be the first company to receive a broad European license for this disease," said Thomas Glanzmann, senior vice president and president, Baxter BioScience. "It underscores our commitment to providing critical therapies for people with unmet medical needs."

Protein C is a component in human plasma which regulates the coagulation system and prevents abnormal clot formation (thrombosis). Currently, there is no ideal alternative to specific protein C replacement therapy. Protein C may be replaced with fresh frozen plasma, but this involves infusing patients with very large volumes of plasma, which can result in fluid overload, causing pulmonary edema and hypertension. Other treatment approaches, such as oral anticoagulation, are associated with a risk of bleeding as well as inadequate control of the serious and widespread thrombotic disorder.

The incidence of severe hereditary protein C deficiency is approximately 1 in every 200,000 births, and often goes undiagnosed. If left untreated, the thrombotic lesions which develop can result in blindness, severe brain damage, multi-organ failure and death. Baxter intends to initiate clinical trials in acquired Protein C deficiency in the near future.

Baxter is a global medical products and services company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Baxter's products and services in bioscience (biopharmaceuticals, vaccines, biosurgery and transfusion therapies), medication delivery and renal therapy are used by health-care providers and their patients in more than 100 countries.

This news release contains forward-looking statements that involve risks and uncertainties, including those related to timing or results of pending or future clinical trials, actions by regulatory and governmental bodies, technological advances in the medical field, product demand and market acceptance and other risks detailed in the company's filings with Securities and Exchange Commission. These forward -looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

(Baxter and Ceprotin are trademarks of Baxter International Inc. and its affiliates)

FOR ADDITIONAL INFORMATION:

	Media Contacts: Deborah Spak, (847) 948-2349 Tali Kaplan, (818) 550-4680 Hans Vanavermaete, 32-2-650-1703 Investor Contacts: Neville Jeharajah, (847) 948-2875 Mary Kay Ladone, (847) 948-3371